

SAFETY DATA SHEET

1. IDENTIFICATION OF THE MATERIAL AND SUPPLIER

1.1 Product identifier

Product name HY-50 VET

HY-50 (SOLUTION FOR INJECTION) **Synonyms**

1.2 Uses and uses advised against

HORSE TREATMENT ● VETERINARY APPLICATIONS ● VETERINARY USE Uses

For intra-articular and intravenous treatment of lameness caused by joint dysfunction associated with

non-infectious synovitis.

Uses advised against Not for human use. Do not use in cases of joint infection.

1.3 Details of the supplier of the product

Supplier name **DECHRA VETERINARY PRODUCTS NZ LTD**

PO Box 1604, Paraparaumu Beach, 5252, NEW ZEALAND **Address**

Telephone 0800 473 838

info.nz@dechra.com **Fmail** Website http://www.dechra.co.nz/

1.4 Emergency telephone numbers

0800 764 766 (National Poisons Centre NZ) **Emergency**

2. HAZARDS IDENTIFICATION

2.1 Classification of the substance or mixture

NON HAZARDOUS ACCORDING TO NZ ENVIRONMENTAL PROTECTION AUTHORITY CRITERIA

2.2 GHS Label elements

No signal word, pictograms, hazard or precautionary statements have been allocated.

2.3 Other hazards

No information provided.

3. COMPOSITION/INFORMATION ON INGREDIENTS

3.1 Substances / Mixtures

Ingredient	CAS Number	EC Number	Content
NON HAZARDOUS INGREDIENTS	Not Available	Not Available	Remainder
HYALURONIC ACID SODIUM SALT	9067-32-7	618-620-0	1.7%

4. FIRST AID MEASURES

4.1 Description of first aid measures

If in eyes, hold eyelids apart and flush continuously with running water. Continue flushing until advised to

stop by a Poisons Information Centre, a doctor, or for at least 15 minutes.

If inhaled, remove from contaminated area. Apply artificial respiration if not breathing. Inhalation

If skin or hair contact occurs, remove contaminated clothing and flush skin and hair with running water. Skin

Continue flushing with water until advised to stop by a Poisons Information Centre or a doctor.

For advice, contact the National Poisons Centre on 0800 764 766 (0800 POISON) or +643 479 7248 or a Ingestion

doctor (at once). Rinse mouth out with water and give plenty of water to drink.

SDS Date: 13 Oct 2021 Revision No: 1



Page 1 of 6

4.2 Most important symptoms and effects, both acute and delayed

See Section 11 for more detailed information on health effects and symptoms.

4.3 Immediate medical attention and special treatment needed

Treat symptomatically.

5. FIRE FIGHTING MEASURES

5.1 Extinguishing media

Use an extinguishing agent suitable for the surrounding fire.

5.2 Special hazards arising from the substance or mixture

Non flammable. May evolve carbon oxides and hydrocarbons when heated to decomposition.

5.3 Advice for firefighters

Treat as per requirements for surrounding fires. Evacuate area and contact emergency services. Remain upwind and notify those downwind of hazard. Wear full protective equipment including Self Contained Breathing Apparatus (SCBA) when combating fire. Use waterfog to cool intact containers and nearby storage areas.

5.4 Hazchem code

None allocated.

6. ACCIDENTAL RELEASE MEASURES

6.1 Personal precautions, protective equipment and emergency procedures

Wear Personal Protective Equipment (PPE) as detailed in section 8 of the SDS.

6.2 Environmental precautions

Prevent product from entering drains and waterways.

6.3 Methods of cleaning up

Contain spillage, then cover / absorb spill with non-combustible absorbent material (vermiculite, sand, or similar), collect and place in suitable containers for disposal.

6.4 Reference to other sections

See Sections 8 and 13 for exposure controls and disposal.

7. HANDLING AND STORAGE

7.1 Precautions for safe handling

Before use carefully read the product label. Use of safe work practices are recommended to avoid eye or skin contact and inhalation. Observe good personal hygiene, including washing hands before eating. Prohibit eating, drinking and smoking in contaminated areas.

7.2 Conditions for safe storage, including any incompatibilities

Store in a cool, dry, well marked area, removed from incompatible substances, foodstuffs and other drugs. Storage areas and containers should be clearly marked for drug holding, protected from light, freezing or physical damage and tightly sealed when not in use. Keep out of reach of children. Store between 2°C and 8°C.

7.3 Specific end uses

No information provided.

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

8.1 Control parameters

Exposure standards

No exposure standards have been entered for this product.

Biological limits

No biological limit values have been entered for this product.



SDS Date: 13 Oct 2021 Revision No: 1

Page 2 of 6

8.2 Exposure controls

Engineering controls Avoid inhalation. Use in well ventilated areas.

PPF

Eye / Face Wear splash-proof goggles. **Hands** Wear PVC or rubber gloves.

Body Wear coveralls.

Respiratory Where an inhalation risk exists, wear a Type A (Organic vapour) respirator.







9. PHYSICAL AND CHEMICAL PROPERTIES

9.1 Information on basic physical and chemical properties

Appearance VISCOUS CLEAR COLOURLESS LIQUID

Odour ODOURLESS
Flammability NON FLAMMABLE
Flash point NOT RELEVANT
Boiling point NOT AVAILABLE
Melting point NOT AVAILABLE
Evaporation rate NOT AVAILABLE

pH 6.2 to 7.8

Vapour density **NOT AVAILABLE** Relative density **NOT AVAILABLE** Solubility (water) **NOT AVAILABLE** Vapour pressure **NOT AVAILABLE** Upper explosion limit **NOT RELEVANT** Lower explosion limit **NOT RELEVANT Partition coefficient NOT AVAILABLE** Autoignition temperature **NOT AVAILABLE** Decomposition temperature **NOT AVAILABLE Viscosity NOT AVAILABLE NOT AVAILABLE Explosive properties NOT AVAILABLE** Oxidising properties **NOT AVAILABLE** Odour threshold

10. STABILITY AND REACTIVITY

10.1 Reactivity

Carefully review all information provided in sections 10.2 to 10.6.

10.2 Chemical stability

Stable under recommended conditions of storage.

10.3 Possibility of hazardous reactions

Polymerization is not expected to occur.

10.4 Conditions to avoid

Avoid heat, sparks, open flames and other ignition sources.

10.5 Incompatible materials

Incompatible with oxidising agents (e.g. hypochlorites), acids (e.g. nitric acid) and alkalis (e.g. sodium hydroxide).

10.6 Hazardous decomposition products

May evolve carbon oxides and hydrocarbons when heated to decomposition.

11. TOXICOLOGICAL INFORMATION



SDS Date: 13 Oct 2021

11.1 Information on toxicological effects

Acute toxicity This product is used in veterinary applications. Use safe work practices to avoid eye contact, prolonged skin

contact and ingestion. Refer to medical doctor/specialist for advice regarding adverse side effects.

Information available for the ingredients:

Ingredient	Oral LD50	Dermal LD50	Inhalation LC50
HYALURONIC ACID SODIUM SALT	> 800 mg/kg (rat)		

Skin Contact may result in irritation, redness, pain and rash.

Eye Contact may result in irritation, lacrimation, pain and redness.

Sensitisation Not classified as causing skin or respiratory sensitisation.

MutagenicityNot classified as a mutagen.CarcinogenicityNot classified as a carcinogen.ReproductiveNot classified as a reproductive toxin.

STOT - single Not classified as causing organ damage from single exposure. However, high level exposure may result in

exposure headache, nausea and respiratory tract irritation.

STOT - repeated

exposure

Not classified as causing organ damage from repeated exposure.

Aspiration Not classified as causing aspiration.

12. ECOLOGICAL INFORMATION

12.1 Toxicity

No information provided.

12.2 Persistence and degradability

No information provided.

12.3 Bioaccumulative potential

No information provided.

12.4 Mobility in soil

No information provided.

12.5 Other adverse effects

No information provided.

13. DISPOSAL CONSIDERATIONS

13.1 Waste treatment methods

Waste disposal Return to manufacturer/supplier where possible. For small amounts, bury in approved landfill site. Contact

the manufacturer/supplier for additional information (if required).

Legislation Dispose of in accordance with relevant local legislation.

14. TRANSPORT INFORMATION

NOT CLASSIFIED AS A DANGEROUS GOOD ACCORDING TO LAND TRANSPORT RULE: DANGEROUS GOODS 2005; NZS 5433:2012, UN, IMDG OR IATA

	LAND TRANSPORT (NZS 5433)	SEA TRANSPORT (IMDG / IMO)	AIR TRANSPORT (IATA / ICAO)
14.1 UN Number	None allocated.	None allocated.	None allocated.
14.2 Proper Shipping Name	None allocated.	None allocated.	None allocated.
14.3 Transport hazard class	None allocated.	None allocated.	None allocated.
14.4 Packing Group	None allocated.	None allocated.	None allocated.



SDS Date: 13 Oct 2021

14.5 Environmental hazards

Not a Marine Pollutant.

14.6 Special precautions for user

Hazchem code None allocated.

15. REGULATORY INFORMATION

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

Approval code None allocated.

Group standard None allocated.

ACVM Number A011417

Inventory listings AUSTRALIA: AIIC (Australian Inventory of Industrial Chemicals)

All components are listed on AIIC, or are exempt.

NEW ZEALAND: NZIoC (New Zealand Inventory of Chemicals)All components are listed on the NZIoC inventory, or are exempt.

16. OTHER INFORMATION

Additional information

WORKPLACE CONTROLS AND PRACTICES: Unless a less toxic chemical can be substituted for a hazardous substance, ENGINEERING CONTROLS are the most effective way of reducing exposure. The best protection is to enclose operations and/or provide local exhaust ventilation at the site of chemical release. Isolating operations can also reduce exposure. Using respirators or protective equipment is less effective than the controls mentioned above, but is sometimes necessary.

RESPIRATORS: In general the use of respirators should be limited and engineering controls employed to avoid exposure. If respiratory equipment must be worn ensure correct respirator selection and training is undertaken. Remember that some respirators may be extremely uncomfortable when used for long periods. The use of air powered or air supplied respirators should be considered where prolonged or repeated use is necessary.

PERSONAL PROTECTIVE EQUIPMENT GUIDELINES:

The recommendation for protective equipment contained within this report is provided as a guide only. Factors such as form of product, method of application, working environment, quantity used, product concentration and the availability of engineering controls should be considered before final selection of personal protective equipment is made.

HEALTH EFFECTS FROM EXPOSURE:

It should be noted that the effects from exposure to this product will depend on several factors including: form of product; frequency and duration of use; quantity used; effectiveness of control measures; protective equipment used and method of application. Given that it is impractical to prepare a report which would encompass all possible scenarios, it is anticipated that users will assess the risks and apply control methods where appropriate.



SDS Date: 13 Oct 2021

Abbreviations ACGIH American Conference of Governmental Industrial Hygienists

CAS # Chemical Abstract Service number - used to uniquely identify chemical compounds

CCID Chemical Classification and Information Database (HSNO)

CNS Central Nervous System

EC No. EC No - European Community Number

EMS Emergency Schedules (Emergency Procedures for Ships Carrying Dangerous

Goods)

EPA Environmental Protection Authority [New Zealand]

GHS Globally Harmonized System

HSNO Hazardous Substances and New Organisms
IARC International Agency for Research on Cancer

LC50 Lethal Concentration, 50% / Median Lethal Concentration

LD50 Lethal Dose, 50% / Median Lethal Dose

mg/m³ Milligrams per Cubic Metre
OEL Occupational Exposure Limit

pH relates to hydrogen ion concentration using a scale of 0 (high acidic) to 14 (highly

alkaline).

ppm Parts Per Million

STEL Short-Term Exposure Limit

STOT-RE Specific target organ toxicity (repeated exposure)
STOT-SE Specific target organ toxicity (single exposure)

TLV Threshold Limit Value TWA Time Weighted Average

Report status

This document has been compiled by RMT on behalf of the manufacturer, importer or supplier of the product and serves as their Safety Data Sheet ('SDS').

It is based on information concerning the product which has been provided to RMT by the manufacturer, importer or supplier or obtained from third party sources and is believed to represent the current state of knowledge as to the appropriate safety and handling precautions for the product at the time of issue. Further clarification regarding any aspect of the product should be obtained directly from the manufacturer, importer or supplier.

While RMT has taken all due care to include accurate and up-to-date information in this SDS, it does not provide any warranty as to accuracy or completeness. As far as lawfully possible, RMT accepts no liability for any loss, injury or damage (including consequential loss) which may be suffered or incurred by any person as a consequence of their reliance on the information contained in this SDS.

Prepared by

Risk Management Technologies 5 Ventnor Ave, West Perth Western Australia 6005 Phone: +61 8 9322 1711 Fax: +61 8 9322 1794 Email: info@rmt.com.au Web: www.rmtglobal.com

[End of SDS]

Page 6 of 6



SDS Date: 13 Oct 2021